New Risk • Jun 03
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 81% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr56m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 46% per year over the past 5 years. Shareholders have been substantially diluted in the past year (81% increase in shares outstanding). Minor Risk Market cap is less than US$100m (kr137.9m market cap, or US$14.8m). Reported Earnings • May 19
First quarter 2026 earnings released: kr0.50 loss per share (vs kr1.22 loss in 1Q 2025) First quarter 2026 results: kr0.50 loss per share (improved from kr1.22 loss in 1Q 2025). Revenue: kr70.4m (up 27% from 1Q 2025). Net loss: kr21.8m (loss narrowed 29% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 31% per year, which means it has not declined as severely as earnings. Tillkännagivande • May 13
Vimab Group AB (publ), Annual General Meeting, Jun 09, 2026 Vimab Group AB (publ), Annual General Meeting, Jun 09, 2026, at 10:00 W. Europe Standard Time. Location: wigge & partners law kb`s premises, at birger jarlsgatan 25 in, stockholm Sweden Reported Earnings • Mar 17
Full year 2025 earnings released: kr3.90 loss per share (vs kr3.31 loss in FY 2024) Full year 2025 results: kr3.90 loss per share (further deteriorated from kr3.31 loss in FY 2024). Revenue: kr328.6m (up 1.0% from FY 2024). Net loss: kr101.7m (loss widened 32% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 37% per year whereas the company’s share price has fallen by 41% per year. New Risk • Jan 12
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: kr89.5m (US$9.74m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-kr7.1m). Earnings have declined by 30% per year over the past 5 years. Market cap is less than US$10m (kr89.5m market cap, or US$9.74m). Minor Risk Share price has been volatile over the past 3 months (9.6% average weekly change). Tillkännagivande • Dec 03
Vimab Group AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 127.416758 million. Vimab Group AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 127.416758 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 26,545,158
Price\Range: SEK 4.8
Transaction Features: Rights Offering New Risk • Dec 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr52m free cash flow). Negative equity (-kr7.1m). Earnings have declined by 30% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (kr110.4m market cap, or US$11.7m). Reported Earnings • Nov 10
Third quarter 2025 earnings released: kr0.20 loss per share (vs kr0.49 loss in 3Q 2024) Third quarter 2025 results: kr0.20 loss per share (improved from kr0.49 loss in 3Q 2024). Revenue: kr94.4m (up 24% from 3Q 2024). Net loss: kr5.03m (loss narrowed 57% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 12% per year. Reported Earnings • Aug 31
Second quarter 2025 earnings released: kr0.40 loss per share (vs kr0.16 loss in 2Q 2024) Second quarter 2025 results: kr0.40 loss per share (further deteriorated from kr0.16 loss in 2Q 2024). Revenue: kr84.6m (down 12% from 2Q 2024). Net loss: kr11.2m (loss widened 208% from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 6% per year. New Risk • Jun 07
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr8.8m free cash flow). Earnings have declined by 18% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (kr211.3m market cap, or US$21.9m). Reported Earnings • May 22
First quarter 2025 earnings released: kr1.20 loss per share (vs kr0.80 loss in 1Q 2024) First quarter 2025 results: kr1.20 loss per share (further deteriorated from kr0.80 loss in 1Q 2024). Revenue: kr56.7m (down 16% from 1Q 2024). Net loss: kr30.9m (loss widened 72% from 1Q 2024). Tillkännagivande • May 14
Vimab Group AB (publ), Annual General Meeting, Jun 10, 2025 Vimab Group AB (publ), Annual General Meeting, Jun 10, 2025, at 10:00 W. Europe Standard Time. Location: at wigge & partners advokat kb`s premises, at birger jarlsgatan 25, stockholm Sweden Reported Earnings • Mar 13
Full year 2024 earnings released: kr3.60 loss per share (vs kr0.20 loss in FY 2023) Full year 2024 results: kr3.60 loss per share (further deteriorated from kr0.20 loss in FY 2023). Revenue: kr330.2m (down 3.5% from FY 2023). Net loss: kr76.9m (loss widened kr72.7m from FY 2023). New Risk • Mar 13
New major risk - Revenue and earnings growth Earnings have declined by 2.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 2.7% per year over the past 5 years. Minor Risk Market cap is less than US$100m (kr173.3m market cap, or US$17.0m). Tillkännagivande • Dec 21
An undisclosed buyer signed a letter of intent to acquire Vimab Ab from Vimab Group AB (publ) (OM:VIMAB) for SEK 200 million. An undisclosed buyer signed a letter of intent to acquire Vimab Ab from Vimab Group AB (publ) (OM:VIMAB) for SEK 200 million on December 19, 2024. The divestment is intended to take place for a purchase price of approximately SEK 200 million on a cash and debt-free basis, which will be paid in cash when the shares are acquired. Net sales for Vimab AB in the financial year 2023 amounted to approximately SEK 200.1 million with an EBITDA result of approximately SEK 23.1 million, which corresponds to an EBITDA margin of approximately 11.5 percent. The divestiture is conditional on the Stakeholder's due diligence and the parties agreeing to enter into a share transfer agreement. Signing of the share transfer agreement and access is planned for the first quarter of 2025. Mangold Fondkommission AB acted as financial advisor for Vimab Group AB. Wigge & Partners Advokat Kb acted as legal advisor for Vimab Group AB. New Risk • Nov 05
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr5.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr5.8m free cash flow). Share price has been highly volatile over the past 3 months (34% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (kr259.6m market cap, or US$24.2m). Reported Earnings • Aug 25
Second quarter 2024 earnings released: kr0.20 loss per share (vs kr0.36 profit in 2Q 2023) Second quarter 2024 results: kr0.20 loss per share (down from kr0.36 profit in 2Q 2023). Revenue: kr96.7m (up 8.2% from 2Q 2023). Net loss: kr3.63m (down 150% from profit in 2Q 2023). Reported Earnings • May 09
First quarter 2024 earnings released: kr0.80 loss per share (vs kr0.53 loss in 1Q 2023) First quarter 2024 results: kr0.80 loss per share (further deteriorated from kr0.53 loss in 1Q 2023). Revenue: kr68.5m (up 72% from 1Q 2023). Net loss: kr17.9m (loss widened 72% from 1Q 2023). Tillkännagivande • May 08
Vimab Group AB (publ), Annual General Meeting, Jun 04, 2024 Vimab Group AB (publ), Annual General Meeting, Jun 04, 2024, at 10:00 W. Europe Standard Time. Location: wigge & partners advokat kb`s, premises at birger jarlsgatan 25, stockholm Sweden Reported Earnings • Mar 13
Full year 2023 earnings released: kr0.30 loss per share (vs kr3.44 loss in FY 2022) Full year 2023 results: kr0.30 loss per share (improved from kr3.44 loss in FY 2022). Revenue: kr347.8m (up 53% from FY 2022). Net loss: kr4.26m (loss narrowed 88% from FY 2022). Reported Earnings • Nov 15
Third quarter 2023 earnings released: EPS: kr0.20 (vs kr0.49 loss in 3Q 2022) Third quarter 2023 results: EPS: kr0.20 (up from kr0.49 loss in 3Q 2022). Revenue: kr99.7m (up 69% from 3Q 2022). Net income: kr4.86m (up kr12.0m from 3Q 2022). Profit margin: 4.9% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue.